Theratechnologies宣布AASLD的口头报告数据，显示Tesamorelin如何减

StephenW

Theratechnologies Announces Data From Oral Presentation at AASLD Showing How Tesamorelin Can Reduce Fibrosis and NASH
Email Print Friendly Share
November 16, 2020 10:31 ET | Source: Theratechnologies
multilang-release

MONTREAL, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today highlighted new data on the mechanism of effect of tesamorelin presented in an oral presentation given today by Lindsay T. Fourman, M.D., of the Metabolism Unit, Department of Medicine, Massachusetts General Hospital, at The Liver Meeting® 2020 of the American Association for the Study of Liver Diseases (AASLD).

Results from a new proteomics sub-analysis presented by Dr. Fourman show that serum levels of three proteins associated with the development of Nonalcoholic Steatohepatitis (NASH) and fibrosis, Vascular Endothelial Growth Factor A (VEGFA), Transforming Growth Factor Beta 1 (TGFβ1) and Colony Stimulating Factor 1 (CSF1), were significantly reduced in tesamorelin patients compared to the placebo group. Specifically, the difference in serum levels, consistent with downregulation in hepatic gene expression, of VEGFA was log2-fold, -0.24 (p=0.03), TGFβ1 was log2-fold -0.31 (p=0.03) and CSF1 log2-fold -0.19 (p=0.004).

“These results help to further our understanding as to how tesamorelin works to reduce liver fat and fibrosis. The impact of tesamorelin on serum level reduction of three proteins associated with NASH progression is yet another indication of the potential benefits of developing tesamorelin for the treatment of NASH”, said Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer, Theratechnologies.

This sub-study extended results previously obtained from the transcriptomic analysis of the liver biopsies for the tesamorelin study in HIV patients with Nonalcoholic Fatty Liver Disease (NAFLD). These prior results were published in JCI Insight in 2020 and The Lancet HIV in October 2019. Results from this current sub-analysis help to better understand the mechanisms behind the effect of tesamorelin on ballooning, inflammation and fibrosis observed in NAFLD and NASH.

“In addition to its known effects to decrease liver fat, these results show that tesamorelin might induce key metabolic pathways that could have a direct effect on inflammation and fibrosis”, said Dr. Steven Grinspoon, Professor of Medicine, Harvard Medical School, Chief of the Metabolism Unit at Massachusetts General Hospital. “These results are additional evidence that support the development of tesamorelin for the treatment of NASH”, concluded Dr. Grinspoon.

About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.

StephenW

Theratechnologies宣布AASLD的口头报告数据，显示Tesamorelin如何减少纤维化和NASH
电子邮件打印友好分享
美国东部时间2020年11月16日10:31 |资料来源：Theratechnologies
多语言发布

蒙特利尔，2020年11月16日（全球新闻）-专注于创新疗法的开发和商业化的生物制药公司Theratechnologies Inc.沙莫瑞林的作用今天在美国肝病研究协会（AASLD）2020年肝脏会议®上由马萨诸塞州总医院医学系代谢科医师Lindsay T. ）。

Fourman博士提出的新的蛋白质组学子分析结果表明，血清中三种与非酒精性脂肪性肝炎（NASH）和纤维化，血管内皮生长因子A（VEGFA），转化生长因子Beta 1（TGFβ1）相关的蛋白水平与安慰剂组相比，替沙莫林患者的血浆中的碳氢化合物和集落刺激因子1（CSF1）明显降低。具体而言，与肝基因表达下调相一致的VEGFA的血清水平差异为log2倍，-0.24（p = 0.03），TGFβ1为log2倍-0.31（p = 0.03）和CSF1 log2倍-0.19 （p = 0.004）。

“这些结果有助于加深我们对tesamorelin如何减少肝脏脂肪和纤维化的理解。 Theratechnologies高级副总裁兼首席医学官Christian Marsolais博士说，替沙莫林对与NASH进展相关的三种蛋白质的血清水平降低的影响，再次表明开发替沙莫林可治疗NASH的潜在益处。

该子研究扩展了先前从替沙莫林研究中针对非酒精性脂肪性肝病（NAFLD）的HIV患者肝活检的转录组分析获得的结果。这些先前的结果发表在2020年的JCI Insight和2019年10月的《柳叶刀》 HIV上。本次亚分析的结果有助于更好地了解替沙莫林对NAFLD和NASH中观察到的气球，炎症和纤维化作用的机制。

哈佛医学院医学院教授史蒂芬·格林斯庞恩博士说：“除了已知的减少肝脏脂肪的作用外，这些结果还表明，替沙莫林可能会诱导可能直接影响炎症和纤维化的关键代谢途径。”麻省总医院新陈代谢科。 Grinspoon博士总结说：“这些结果是支持替沙莫林开发NASH的其他证据。”

关于戏剧学
Theratechnologies（TSX：TH）（NASDAQ：THTX）是一家生物制药公司，致力于满足未满足的医疗需求的创新疗法的开发和商业化。有关Theratechnologies的更多信息，请访问公司的网站www.theratech.com，SEDAR的www.sedar.com和EDGAR的www.sec.gov。